MedTwenty Indices and trackers are editorial indicators and business information. They are not investment, financial, legal or medical advice, and not a regulated benchmark.
Summary
Global pharmaceutical company, first to market with an oral PCSK9 inhibitor following FDA approval of Lipfendra.
Finances
Not published (small company accounts)
Timeline
No verified timeline entries yet.